Legato Capital Management LLC Buys 41,323 Shares of NeuroPace, Inc. $NPCE

Legato Capital Management LLC boosted its stake in shares of NeuroPace, Inc. (NASDAQ:NPCE) by 190.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 63,045 shares of the company’s stock after purchasing an additional 41,323 shares during the period. Legato Capital Management LLC owned about 0.19% of NeuroPace worth $650,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of NPCE. AlphaQuest LLC purchased a new stake in NeuroPace in the second quarter worth about $82,000. Y Intercept Hong Kong Ltd bought a new position in shares of NeuroPace during the 2nd quarter valued at approximately $600,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of NeuroPace during the 2nd quarter valued at approximately $173,000. Geode Capital Management LLC increased its holdings in NeuroPace by 44.6% in the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company’s stock worth $5,406,000 after acquiring an additional 149,595 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in NeuroPace by 72.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock worth $71,000 after acquiring an additional 2,668 shares during the period. Institutional investors own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on NPCE shares. HC Wainwright upped their price target on shares of NeuroPace from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Wells Fargo & Company lifted their target price on shares of NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a report on Monday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of NeuroPace in a report on Wednesday, November 5th. Finally, Leerink Partners restated an “outperform” rating and issued a $19.00 price objective on shares of NeuroPace in a research report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

More NeuroPace News

Here are the key news stories impacting NeuroPace this week:

• Positive Sentiment: Q4 top-line and EPS beat — Revenue of $26.6M (+24% YoY) and an EPS loss smaller than expected; RNS System revenue grew ~26%, signaling healthy product adoption. NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Company reiterated its 2026 outlook and provided a full press release & corporate update reinforcing operational progress and revenue trajectory. NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
• Neutral Sentiment: Management hosted an earnings call; transcripts and highlights are available for color on execution, margins and commercialization cadence (useful for longer-term thesis, less immediate price impact). NeuroPace (NPCE) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Full-year revenue guidance was provided at roughly $98.0M–$100.0M, which is close to consensus (~$98.7M) — this reduces surprise risk but is not a clear upside catalyst. NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
• Negative Sentiment: Q1 2026 revenue guidance of $21.0M–$22.0M is materially below the street (~$25.3M), creating near-term downside risk to estimates and investor confidence. NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
• Negative Sentiment: Company remains unprofitable with negative margins and high leverage metrics noted in recent summaries, factors that can amplify price volatility if growth slows. Listen to Conference Call / Press Release

NeuroPace Price Performance

Shares of NASDAQ:NPCE opened at $13.95 on Thursday. The firm has a market cap of $464.67 million, a price-to-earnings ratio of -21.14 and a beta of 1.86. The firm has a fifty day moving average price of $15.63 and a 200 day moving average price of $13.27. NeuroPace, Inc. has a fifty-two week low of $7.56 and a fifty-two week high of $18.98. The company has a debt-to-equity ratio of 3.17, a quick ratio of 3.94 and a current ratio of 4.86.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. NeuroPace had a negative net margin of 21.47% and a negative return on equity of 103.49%. The company had revenue of $26.59 million for the quarter, compared to the consensus estimate of $24.79 million. As a group, sell-side analysts expect that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

NeuroPace Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.